KRAS and colorectal cancer: Jung et al. [82] conducted a whole-genome CRISPR/Cas9 screen and found that the resistance to the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancer cells is associated with activation of the WNT pathway.